ATP Clinical Research, Inc.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease5 trials
• Depression2 trials
• Schizophrenia2 trials

Phase

• Phase 35 trials

Status

• Completed4 trials
• Terminated2 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial
• Recruiting1 trial

Lead sponsor

• Cassava Sciences, Inc.2 trials
• Cognito Therapeutics, Inc.2 trials
• LivaNova2 trials
• Boehringer Ingelheim1 trial
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
• and 1 more

Running trials

• Enrolling by invitation

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Cognito Therapeutics, Inc.· Source

• Active, not recruiting

  Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

  NCT05397639· Phase 3· Suven Life Sciences Limited· Source

• Recruiting

  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  NCT03887715· LivaNova· Source

  Contact: Bobby Shih

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• Depression1 recruiting

Closed trials

• Completed

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Cognito Therapeutics, Inc.· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Terminated

  The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

  NCT04753385· LivaNova· Source